Startup Nido Bio Reveals $109M (so far) for Precision Approach to Neuro Disorders
Nido Biosciences’ lead drug hits a previously undrugged pocket as a way to potentially treat the rare neuromuscular disorder spinal and bulbar muscular atrophy. The startup’s tech platform screens neurons to find targets for new neurological disorder drugs.